Core Insights - Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all patent disputes related to its biosimilar of Eylea, which is approved for marketing in several regions [1][2][3] Group 1: Licensing and Market Entry - The settlement allows Alvotech to market and sell the biosimilar starting January 1, 2026, in the UK and Canada, and in Japan from May 1, 2026, excluding diabetic macular edema [2] - The biosimilar will be available in the European Economic Area and other countries (excluding the U.S.) from May 1, 2026, and in Japan with all approved indications from November 1, 2026 [2] Group 2: Commercial Partnerships - Alvotech's commercial partners for the Eylea biosimilar in Europe include Advanz Pharma (UK/EEA), STADA (Germany), and Biogaran (France), with Fuji Pharma Ltd. as the partner in Japan [4] - The biosimilar is marketed under the names Mynzepli and Afiveg in Europe and as AFLIBERCEPT BS in Japan [5] Group 3: Product Information - AVT06, the biosimilar to Eylea, inhibits vascular endothelial growth factors (VEGF), which are crucial in treating various retinal diseases [5] - Aflibercept remains a widely used treatment for retinal diseases, and Alvotech aims to support its commercial partners in launching the product successfully [3]